IntelGenx Technologies Corp. operates as a specialized drug delivery firm, concentrating on the creation and production of innovative oral thin film products for the pharmaceutical industry. Their current portfolio features several oral film formulations: INT0008/2008, a Rizatriptan product addressing migraine headaches; INT0046/2018, intended for adult applications; INT0007/2006, developed for the treatment of erectile dysfunction; INT0043/2015, a montelukast-based film for Alzheimer's disease; INT0027/2011, aimed at combating opioid addiction; INT0010/2006, designed to alleviate neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film for schizophrenia or bipolar 1 disorder; and INT0048/2020, catering to animal health. Furthermore, IntelGenx is advancing additional projects in its development pipeline, specifically INT0039/2013, INT0040/2014, INT0052/2020, INT0053/2020, and INT0054/2020.